Several studies focused on acute myeloid leukemia, lymphoma, and MM have shown that a series of bortezomib-adapted cell lines developed from the above malignancies exhibit higher PSMB5 expression at the both RNA and protein levels than the respective parental bortezomib-sensitive cells [16-19]. The gene discussed is PSMB5; the disease is lymphoma.